stockrowBruker Corporation
BRKR Healthcare Medical Devices
Bruker Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.4 billion, up 2.08% from fiscal 2024.
- Revenue
- +1.57%
- EPS
- −75.4%
- Free cash flow
- +278.7%
- Total debt
- −14.7%
Quarter to September 2026, against a year earlier
Follow BRKR
Alert me
Bruker Corporation (BRKR) EBITDA
Bruker Corporation's EBITDA for fiscal 2025 was $288.5M, down 34.0% from $436.9M in fiscal 2024. Over the twelve months to 30 September 2026 it was $158.7M. Over the past ten years it has ranged from $199.0M (fiscal 2015) to $551.8M (fiscal 2023); the current reading is higher than 36% of that period. Bruker Corporation ranks 24th of 147 Medical Devices companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $288.5M | (33.97%) |
| FY2024 | $436.9M | (20.82%) |
| FY2023 | $551.8M | 5.81% |
| FY2022 | $521.5M | 3.80% |
| FY2021 | $502.4M | 52.84% |
| FY2020 | $328.7M | (12.70%) |
| FY2019 | $376.5M | 15.03% |
| FY2018 | $327.3M | 15.49% |
| FY2017 | $283.4M | 20.03% |
| FY2016 | $236.1M | 18.64% |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | −$7.3M | — |
| Mar 2026 | $68.5M | (49.03%) |
| Dec 2025 | $134.4M | 3,346.15% |
| Sep 2025 | $3.9M | (94.26%) |
| 42 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| SNN Smith & Nephew SNATS, Inc. compare | $2.6B |
| GMED Globus Medical, Inc. compare | $932.9M |
| PODD Insulet Corporation compare | $693.3M |
| PEN Penumbra, Inc. compare | $209.4M |
| BRKR Bruker Corporation | $158.7M |
| TXG 10x Genomics compare | −$40.4M |
| BIO.B Bio-Rad Laboratories, Inc. compare | −$61.9M |
| BIO Bio-Rad Laboratories, Inc. compare | −$61.9M |
| GKOS Glaukos Corporation compare | −$130.8M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on BRKR
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement